Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress by Zhi-yu Chen et al.
Chen et al. Lipids in Health and Disease 2014, 13:98
http://www.lipidworld.com/content/13/1/98RESEARCH Open AccessAtorvastatin helps preserve pancreatic β cell
function in obese C57BL/6 J mice and the effect
is related to increased pancreas proliferation and
amelioration of endoplasmic-reticulum stress
Zhi-yu Chen, Shuai-nan Liu, Cai-na Li, Su-juan Sun, Quan Liu, Lei Lei, Li-hui Gao and Zhu-fang Shen*Abstract
Background: 3-Hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitors or statins are competitive inhibitors of
the rate-limiting enzyme in cholesterol biosynthesis. Currently, statins are used as first-line therapy in the treatment of
diabetic dyslipidemia. However, effects of statins on β cell function remains unclear. This study aims to examine effects
of atorvastatin treatment on pancreatic β cell function in obese C57BL/6 J mice and the possible mechanisms.
Methods: Diet-induced obesity (DIO) C57BL/6 J mice were treated with atorvastatin (30 mg/kg/day) for 58 days. β
cell function was assessed by hyperglycemic clamp and the area of insulin-positive β cells was examined by
immunofluorescence. Gene expression was assessed by RT-PCR, and endoplasmic reticulum (ER) stress related
proteins were examined by Western blot. Additionally, cell viability and apoptosis of the cholesterol-loaded NIT-1
cells were investigated after atorvastatin treatment.
Results: Hyperglycemic clamp study revealed that glucose infusion rate (GIR) and insulin stimulation ratio in
atorvastatin-treated DIO mice were markedly higher than control mice (P < 0.05, P < 0.01 vs. con), indicating
preserved β-cell sensitivity to glucose. Lipid profiles of plasma triglyceride (TG), pancreas TG and plasma cholesterol
(CHO) were improved. Pancreas weight and weight index were improved significantly after atorvastatin treatment
(P < 0.05 vs. con). Immunofluorescence results showed that atorvastatin-treated mice had significantly larger
insulin-positive β cell area (P < 0.05 vs. con). Furthermore, RT-PCR and western blot showed that the mRNA and
protein expression of pancreatic and duodenal homeobox 1 (Pdx1) in the pancreas were upregulated (P < 0.001,
P < 0.01 vs. con). Moreover, the expression level of ER stress markers of activating transcription factor 4 (ATF4),
CCAAT-enhancer-binding protein homologous protein (CHOP) and phosphorylated eukaryotic initiation factor 2α
(eIF2α) were downregulated in the pancreas of atorvastatin-treated mice (P < 0.001, P < 0.01, P < 0.01 vs. con).
Besides, atorvastatin protected the pancreatic β cell line of NIT-1 from cholesterol-induced apoptosis. Western blot
showed increased expression of anti-apoptotic protein of B-cell lymphoma 2 (Bcl-2).
Conclusion: Pancreatic β cell function of obese C57BL/6 J mice was preserved after atorvastatin treatment, and
this improvement may be attributed to enhanced pancreas proliferation and amelioration of pancreatic ER stress.
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Statins are potent inhibitors of cholesterol biosyn-
thesis. This class of agents have been used as lipid-
altering agents, and exhibit beneficial effects on
reducing cardiovascular risks [1-3]. Meanwhile, as the
risks of cardiovascular disease are elevated in type 2
diabetes mellitus [4], statin therapy is indicated in
metabolic syndrome and diabetic patients with cardio-
vascular risks [5,6].
Thus, whether statin therapy affects development of
diabetes and which aspect of diabetes it will affect is in-
triguing. Pathological factors such as insulin resistance
and β-cell failure have to be taken into account. On the
one hand, recent studies showed that beneficial effect of
atorvastatin on insulin resistance were due to decrease of
inflammation [7]. On the other hand, functional β-cell
mass was expanded with atorvastatin in the neonatal
rodent [8]. However, whether the β-cell function will be
affected is a concern. Clinical study of DIATOR trial
showed that atorvastatin was effective in slowing the
decline of beta cell function [9]. Besides, diabetes hazard
was reduced by 30% in WOSCOPS trial [10]. Hence, we
hypothesized that statin would positively affect β-cell
function.
Many factors contribute to β-cell dysfunction, such as
ER stress and mitochondrial dysfunction. It is reported
that ER stress plays pivotal roles in both insulin resist-
ance and β-cell failure. Markers of ER stress are elevated
in the liver and adipose tissue in diet-induced forms of
obesity and insulin action is interfered [11]. As ER
serves as the protein folding factory for insulin [12],
higher demand for insulin biosynthesis and secretion
caused by long term over-nutrition will probably induce
ER stress, and gradually leads to β-cell failure [13]. Evi-
dences of the correlation between ER stress and dia-
betes also come from observations that humans and
mice that have mutations in ER stress markers of
double-stranded RNA-dependent protein kinase (PERK)
and eIF2α are severely diabetic [14,15]. The islets of dia-
betic db/db mice show increased eIF2α phosphorylation
and up-regulation of ATF4 and CHOP, indicating the
presence of ER stress [16]. As atorvastatin showed
beneficial effects on improving insulin sensitivity, we
hypothesized the burden of ER to secret insulin was
decreased and ER stress might be alleviated.
In our study, we used the insulin-resistant obese
C57BL/6 J mice to assess the effects of atorvastatin on β
cell function, β cell apoptosis and ER stress. It is shown
that atorvastatin- treated mice had enhanced lipid pro-
files, β cell sensitivity to glucose, β cell proliferation and
ameliorated ER stress state compared to the control
mice. Atorvastatin also protected NIT-1 β cell line from
apoptosis induced by cholesterol and increased anti-
apoptosis protein of Bcl-2. Taken together, atorvastatintreatment benefits pancreatic β cell function through
improved proliferation and attenuated ER stress.
Results
Atorvastatin improves β-cell sensitivity to glucose and
lipid profiles of obese C57BL/6 J mice
Using the hyperglycemic clamp, we examined the β-cell
function. Relatively similar blood glucose concentrations
of ~14 mmol/l of steady states were achieved by 135 min of
glucose infusion in both groups (Figure 1A). In the
atorvastatin-treated group, GIR which symbolizes the glu-
cose metabolism was elevated approximately 2 fold (46.0 ±
1.8 mg/kg/min) compared with the control group (20.8 ±
2.2 mg/kg/min, P < 0.05 vs. controls) (Figure 1B). Fasting
plasma insulin level of control mice was significantly higher
than mice treated with atorvastatin (Figure 1C, P < 0.05),
which indicated more severe insulin resistance state. The
insulin secretion responses were biphasic, but the insulin
stimulation rates at 5 minutes and steady state were much
higher in atorvastatin group than control group (Figure 1D,
P < 0.01). This implied the improved β-cell sensitivity to
glucose after atorvastatin treatment. Besides, fasting insulin
levels of the left C57BL/6 J mice in each group also showed
that atorvastatin was beneficial for amelioration of insulin
resistance (Figure 1E, P < 0.05 vs. con).
We further examined the lipid profiles of atorvastatin-
treated mice. On day 58, plasma TG and pancreas TG
were both diminished obviously (P < 0.05, P < 0.001 vs.
con) in atorvastatin group (Table 1). Plasma CHO but not
pancreas CHO decreased significantly (Table 1, P < 0.05).
These results suggested that the lipid files were greatly im-
proved in atorvastatin group.Atorvastatin increases pancreas weight and weight index,
and helps improve insulin positive β-cell area
We further examined the pancreas weight and calcu-
lated pancreas weight index. Pancreas weight was
much heavier in atorvastatin group than control group
(Table 2, P < 0.05), and the pancreas weight index was
larger than that of control group (Table 2, P < 0.05).
These results suggested atorvastatin might increase
the pancreas proliferation. Thus, we observed the
morphology of islet by H&E staining and immuno-
fluorescence. The results showed that the area of
insulin-positive granule of obese C57BL/6 J mice was
significantly enlarged with irregular shape compared to
the non-obese control mice, underlying the existence of
compensatory hypertrophy of islets. Atorvastatin treat-
ment could improve the shape of islets and increase the
area of insulin positive granule, suggesting that atorva-
statin might increase the insulin biosynthesis and content.
(atorvastatin 50389.2 ± 7494.8 μm2 vs. control 21337.9 ±
3151.8 μm2, P < 0.5, Figure 2A-C).























































































































Figure 1 Atorvastatin improves the β-cell sensitivity to glucose in obese C57 mice and decreases fasting insulin level. Pancreatic beta
cell function was evaluated by hyperglycemic clamp. After sampling (t = 0 min) for the assay of the basal blood glucose and insulin, animals
received intravenously glucose bolus followed by a constant infusion of glucose to maintain plasma glucose level at 14 mmol/l. (A) Plasma glucose
level, (B) Glucose infusion rates (GIR), (C) Plasma insulin level, (D) Insulin stimulation ratio, and (E) fasting insulin level. Results are means ± S.E.M.
(n = 4-5). *P < 0.05, **P < 0.01 vs. control.
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and suppresses ER stress by downregulating the
peIF2α-ATF4-CHOP pathway
To determine whether there is a specified mechanism of
effects of atorvastatin, we examined the pancreas gene ex-
pression. Pdx-1, a critical molecule for pancreatic cell pro-
liferation and Liver X receptor β (LXR-β), which plays a
crucial role in the control of lipid metabolism were signifi-
cantly up-regulated by atorvastatin (Figure 3A, P < 0.001).
Western blot further confirmed that the protein level of
Pdx-1was markedly higher in the pancreas of atorvastatin
treated mice compared with the control mice (Figure 3B).
These findings suggested that atorvastatin upregulated
molecules critical for pancreatic cell proliferation and lipid
metabolism.Table 1 Lipid levels in plasma and pancreas of C57 mice
at the end of atorvastatin treatment on day 58
Group Dose
(mg/kg)
TG (mg/dl) CHO (mg/dl)
Plasma Pancreas Plasma Pancreas
Nor – 64.3 ± 5.6** 146.0 ± 23.4*** 85.3 ± 5.9** 12.5 ± 1.5**
Con – 140.0 ± 20.7 340.6 ± 7.9 270.2 ± 36.0 18.7 ± 1.8
Ator 30 84.0 ± 8.6* 212.3 ± 19.5*** 170.5 ± 9.9* 18.2 ± 1.9
Values are mean ± S.E.M, n = 4-6. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.Furthermore, western blot revealed that eIF2α, which is
downstream of PERK and is phosphorylated by PERK in
the unfolded protein response (UPR), was less phosphory-
lated in the pancreas of normal and atorvastatin-treated
mice compared with the control mice (P < 0.01, Figure 3C).
We further examined the effect of atorvastatin on the ex-
pression of ATF4 and CHOP in pancreatic tissues. We
found that, consistent with the result of reduced phosphor-
ylation of eIF2α, the protein levels of ATF4 and CHOP
were both down-regulated significantly in the atorvastatin-
treated mice compared with the control mice (Figure 3D,
E, P < 0.001, P < 0.01 vs. con). These findings implied the
existence of ER stress state in pancreas of obese C57BL/6 J
mice, and atorvastatin could attenuate the ER stress by
modulating the peIF2α-ATF4-CHOP pathway.Table 2 Effects of atorvastatin on pancreas/weight index









Nor – 24.2 ± 0.5*** 0.147 ± 0.007*** 6.1 ± 0.4*
Con – 47.5 ± 2.1 0.232 ± 0.016 4.8 ± 0.4
Ator 30 41.5 ± 2.1 0.279 ± 0.006* 6.8 ± 0.6*








































Figure 2 Atorvastatin helps preserving β-cell area in obese C57 mice. (A) H&E staining of pancreatic islets. (B) Fluorescent staining of
insulin-expressing β-cells (FITC; 20×) in non-obese, obese mice with and without atorvastatin treatmen. (C) Quantification of area of





















































































































Figure 3 Atorvastatin upregulates PDX-1 and LXR-β expression and downregulates the protein expressions of ER stress markers. Total
RNA was extracted from the pancreas of C57 mice and analyzed by quantitative real-time PCR. A comparative threshold cycle (CT) method was
used for relative quantification of gene expression using beta-actin for normalization. Measurements were carried out in triplicate for each sample.
(A) Relative mRNA levels of PDX-1 and LXR-β in pancreatic cells. Western blot analysis of pancreatic (B) PDX-1 (C) phosphorylated eIF2α (D) ATF4
(E) CHOP in C57 mice compared in three groups. Beta actin served as loading control. Data represented the mean of at least three independent
experiments ± S.E.M. **p < 0.01, ***p < 0.001 vs. control.
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apoptosis induced by cholesterol loading
Although proliferative effect was shown after atorva-
statin treatment, it remains unclear whether the expan-
sion of β-cells was also due to decreased apoptosis.
Thus, we investigated whether atorvastatin modulates
the apoptotic response in pancreatic β cell line NIT-1.
First of all, we examined whether atorvastatin affects
the cell viability of NIT-1 cells. Results showed that no ad-
verse effects were exerted on NIT-1 cells viability, and ator-
vastatin 10−7 M-10−5 M significantly increased NIT-1 cells
viability (Figure 4A). This proliferative effect at high con-
centration is corresponding with increased β-cell area ob-
served in C57 mice. Treatment with 0.125 mM cholesterol
for 12 h reduced the viability of NIT-1 cells by 67%
(Figure 4B, P < 0.001). Atorvastatin (10−9-10−5 M) improved
NIT-1 cells viability treated with 0.125 mM cholesterol in a
dose-dependent manner (P < 0.05 for 10−9-10−7 M, P < 0.01
for 10−6-10−5 M, Figure 4B). The viabilities of NIT-1 cells
treated with 10−9 M and 10−5 M atorvastatin were 163%
and 219% higher than NIT-1 cells treated with cholesterol
alone. Flow cytometry analysis further revealed that
cholesterol-treated NIT-1 cells had an apoptotic rate of
33 ± 2.1%, which was reduced to 24 ± 3.8% with 10−8 M
atorvastatin treatment (P < 0.01, Figure 4C). Western blot
additionally revealed that atorvastatin induced up-
regulation of anti-apoptosis protein of Bcl-2 in NIT-1
cells, and this might contribute to the increased NIT-1
cells survival (P < 0.01, Figure 4D).
Discussion
In this study, the effects of atorvastatin treatment on pan-
creatic β cell function in obese C57BL/6 J mice and its
possible mechanism were investigated. After 58 days of
treatment, GIR and insulin stimulation ratio of atorva-
statin treated mice were improved compared with control
mice. Furthermore, these mice had greater insulin positive
β cell area. Besides, pancreas ER stress markers were
down-regulated. In vitro results suggest a protective role
of atorvastatin against cholesterol-induced apoptosis of
NIT-1 cells. All the results indicate the beneficial effects of
atorvastatin on β-cell function.
The hyperglycemic clamp has been demonstrated to be
a reliable technique to evaluate β-cell sensitivity to glucose
[17]. Because the glucose level is held constant, the glu-
cose infusion rate is an index of glucose metabolism. De-
fect of initial phase of insulin secretion is the earliest
detectable abnormality in diabetes mellitus. The insulin
stimulation ratios of first and second phases were both en-
hanced after atorvastatin treatment, indicating a preserved
β cell function.
Up to date, many researchers have showed the benefi-
cial effects of atorvastatin on insulin resistance were due to
amelioration of inflammation [7,18,19]. In hyperglycemicclamp test, the insulin at 0 min in atorvastatin group was
significantly lower (p < 0.05 vs. con), and we confirmed the
result by examining insulin level again when the animals
were sacrificed. The decreased fasting insulin implied the
insulin resistance was ameliorated and this is accordant to
results reported above. It is possible that the decreased de-
mand of insulin could relieve the work burden of ER to
synthesize and secrete insulin. Hence, the ER stress state
was alleviated based on lipid-independent effect.
We observed that 30 mg/kg atorvastatin improved the
lipid profile of obese C57BL/6 J mice. Plasma TG and pan-
creatic TG were both decreased (P < 0.05, P < 0.001 vs.
Con ). TG is reported to activate ER stress, and ER stress
impairs insulin sensitivity by decreasing the tyrosine phos-
phorylation of insulin receptor substrate-1 (IRS-1) [20].
Thus, the lipid-lowering effect of atorvastatin may lead to
amelioration of ER stress and insulin resistance and even-
tually preserved the β-cell function. Moreover, the LXR-β,
which plays a central role in regulation of cholesterol me-
tabolism was also up-regulated in pancreas.
On the other hand, atorvastatin may improve β cell
function through accelerating the pancreas proliferation as
shown by the immunofluorescence results. PDX-1 mRNA
and protein level in pancreas were both increased signifi-
cantly. PDX-1 is important for pancreatic development
and β-cell function. Pdx1+/− mice showed worsening glu-
cose tolerance and insulin secretion and the islets were
more susceptible to apoptosis [21].
Another possible reason of preserved β cell function
could be the improvement of endothelial function. Islet
endothelium plays an important role in providing oxygen
and nutrients to endocrine cells, trans-endothelial rapid
passage of secreted insulin into the circulation and blood
glucose sensing and regulation [22,23]. Endothelial dys-
function has been shown in patients with type 1 and type
2 diabetes mellitus. Improved metabolic control in dia-
betic patients is associated with near restoration of endo-
thelial function [24]. As statins were shown to increase the
expression of eNOS and iNOS [25,26], and may increase
the NO production leading to vascular relaxation. Endo-
thelium function may therefore be improved. Atorvastatin
was reported to improve the regeneration of β-cell mass
due to increase of intro-islet endothelial cells [8].
As the strong association between the ER stress and dia-
betes [27,28], we specifically investigated whether atorva-
statin exerted its effect on pancreatic β cells by modulating
the ER stress. Once the ER stress is present, the UPR will
be triggered to cope with stress conditions. There are three
sensing proteins, inositol-requiring 1α (IRE1α), PERK and
activating transcription factor 6 (ATF6) [29]. As for the
PERK pathway, PERK phosphorylates eIF2α, and this will
cause more efficiently translation of ATF4. Chop is the
downstream protein of PERK–eIF2α–ATF4 pathway and















































































































































Figure 4 Atorvastatin attenuates cholesterol-induced apoptosis of NIT-1 cells. (A) Effects of atorvastatin alone on NIT-1 cell viability. (n = 3–5)
(B) Reserved β-cell relative viability after addition of different concentrations (10−9 to 10−5 M) of atorvastatin under treatment with 0.125 mM cholesterol
for 12 h. Values are means ± S.E.M. (n = 3). (C) NIT-1 cell apoptosis with or without treatment of cholesterol and in addition of 10−8 M atorvastatin
incubation for 18 h. Results were detected by flow cytometry and quantification was made based on propidium iodide (PI) positive cells. (n = 3)
(D) Protein expression of anti-apoptotic Bcl-2 in the pancreas. All the data were expressed as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the
CHO group; ##P < 0.01, ###P < 0.001 vs. control.
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control and expanded beta cell mass [31]. In this study, we
found that eIF2α–ATF4-Chop pathway was turned down
after atorvastatin treatment. However, whether ATF6 and
IRE1α pathways are involved needs to be investigated in
further study.
The cholesterol induced apoptosis model of NIT-1 cells
provides us a tool to investigate the effects of atorvastatin.
Recently, cholesterol has been proved to induce the ER
stress and apoptosis in macrophages [32]. As type 2 dia-
betes is accompanied with inflammation, we mimicked the
ER stress state by loading cholesterol onto NIT-1 cells. We
found that cholesterol suppressed the viability of NIT-1
cells, which was attenuated by atorvastatin in a dose-dependent manner. Flow cytometry test further demon-
strated that atorvastatin ameliorated cholesterol-induced
apoptosis of NIT-1 cells. CHOP was shown to down-
regulate the anti-apoptotic protein of Bcl-2 [33], the pre-
served Bcl-2 expression in NIT-1 cells is accordant with the
depression of CHOP expression in pancreas. Besides, ator-
vastatin alone did not negatively affect NIT-1 cell viability
and increased viability at high concentration. This result
could interpret the increased insulin positive β-cell area ob-
served in C57 mice.
However, some clinical trials have revealed the deterior-
ation of glucose metabolism of statins [6]. And FDA has
expanded advice on statin risks of possibility of developing
type 2 diabetes. The possibility that patients who have
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ing diabetes can’t be expelled. Another explanation is that
long term aggressive therapy with statins could induce the
adverse effects.
In this study, aggressive dose of atorvastatin was used.
The dose of 30 mg/kg/d of atorvastatin in mice is equiva-
lent to 170 mg/d in a 70 Kg human calculated based on
the body surface area (BSA) [34,35]. This is more than the
highest dose of 80 mg/d which is recommended. For
adults with diabetes, the American Diabetes Association
recommends aggressive use of statin in the treatment of
diabetic dyslipidemia [36]. In the REVERSAL trial, aggres-
sive lipid lowering with atorvastatin (80 mg/d) showed
beneficial effects on halting the atherosclerosis progression
(−0.4%) compared with baseline, and the effect is superior
to simvastatin 40 mg [37]. Meanwhile, antioxidant and
anti-inflammation benefits of atorvastatin 80 mg were also
observed in MIRACL and ASAP trails [38,39]. Besides,
the aggressive (80 mg/d) and moderate (10 mg/d) lipid-
lowering therapy with atorvastatin was compared in the
DALI trail [40]. Consequently, Fasting TG was reduced by
35% with aggressive therapy and by 25% with moderate
therapy. Thus, atorvastatin 80 mg/d is of better effects on
lipid file alterations compared with 10 mg/d.
Conclusion
In conclusion, treatment of insulin-resistant obese C57BL/
6 J mice with atorvastatin exhibits a protective effect on
pancreatic β cell function and this is related to increased
pancreas proliferation and decreased ER stress. Our find-
ing is expected to provide evidence for a better and appro-
priate clinical use of atorvastatin.
Methods
Cells
The pancreatic β cell line NIT-1 was purchased from ATCC
(Manassas, VA) and cultured in DMEM/F12 containing
10% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotics
(100 U/mL penicillin and 0.1 mg/ml streptomycin) at 37°C
in a humidified atmosphere containing 5% CO2 [41].
Animals and hyperglycemic clamp studies
All animals were handled in accordance with The Stan-
dards for Laboratory Animals (GB14925-2001) and The
Guideline on the Humane Treatment of Laboratory Ani-
mals (MOST 2006a) established by the People’s Republic
of China. The two guidelines were conducted in adher-
ence to the regulations of Institutional Animal Care and
Use Committee (IACUC) and all animal protocols were
approved by IACUC.
Six-week-old male C57BL/6 J mice (Institute of Labora-
tory Animal Science, CAMS and PUMC, Beijing, China)
were housed in a controlled environment with a 12 h
light/dark cycle (lights on from 6:00 AM to 6:00 PM) atconstant temperature (22–25°C) with ad libitum access to
food and water. Mice were fed with high-fat diets for
20 weeks and were then randomly assigned to receive
atorvastatin at 30 mg/kg/day or vehicle for 58 days by gav-
age with 10 mice per group. High fat diet is kept during
the 58 days. Hyperglycemic studies were conducted as de-
scribed previously [42]. On day 52, after a 10-h fast, mice
(4 to 5 from each group) were anesthetized with pentobar-
bital sodium (50 mg/kg body weight, intraperitoneally)
and placed on a heating pad at 37°C. The right jugular
vein was catheterized (Micro-renathane, 0.025 × 0.012″)
and after a 30 min rest, the mice received a bolus injection
of D-glucose at 0.25 g/kg body weight followed by con-
tinuous infusion of glucose (50%) at 10–20 μL/min. Blood
samples were collected initially (0 min) and then every 5
or 10 min from the tail throughout the test for determin-
ation of glucose concentration using a glucose meter
(ACCU-CHEK Active; Roche, Mannheim, Germany). The
infusion rate of glucose was adjusted according to the re-
sults of plasma glucose concentration to achieve a steady
state with hyperglycemia nearly 14 ± 0.5 mmol/l. At the
end of the clamp, glucose infusion rate (GIR) was calcu-
lated. On day 58, the remaining mice were sacrificed for
additional assays. Body weight and pancreas were weighed
and the pancreas weight index was calculated using the
formula below. Pancreas weight index = pancreas weight
(g)/body weight (g)Histological studies
Pancreatic tissue specimens were fixed in 10% formalin
overnight and then paraffin-embedded and sectioned at a
thickness of 7 μm. The tissue sections were deparaffi-
nized and rehydrated sequentially in xylene, xylene/
ethanol, and gradient ethanol, and then placed in
distilled water for 10 min. Pancreatic tissue sections were
then stained with hematoxylin and eosin (H&E) using
standard protocols.Immunofluorescence
Paraffin-embedded pancreatic tissue sections were dewaxed
using xylene, rehydrated through gradient alcohol [43]. The
sections were washed and incubated with mouse anti-
insulin antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) and then FITC-conjugated goat anti-mouse IgG
(Zhongshan Jinqiao Co., Beijing, China). Images were ob-
tained using a Leica TCS SP2 laser scanning confocal
microscope (Nikon) and analyzed using the Image pro
plus 5.1 image analysis software (Media Cybernetics, Silver
Spring, MD, USA). Three animals were included in each
group. At least three sections from each animal were ana-
lyzed. For each section, the area of insulin positive β-cell
in each islet was determined and the average area was
calculated.
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Total cellular RNA was extracted from the pancreatic tis-
sue of C57BL/6 J mice using Trizol reagent (Invitrogen,
Carlsbad, CA). Reverse transcription reactions for the
preparation of first strand cDNA was performed using
VigoScript First Strand cDNA Synthesis Kit (Vigorous
Biotech- nology Beijing Co., Ltd.). RNase-Free DNase
(Promega, Madison, WI) was used to degrade DNA prior
to qPCR detection. Quantitative real time PCR (qPCR)
was performed on an ABI 7000 Real Time PCR system
(Applied Biosystems, Foster City, CA) using the SYBR
Premix Ex Taq kit (TakaRa, Japan). All samples were an-
alyzed in triplicate and normalized with β-actin used as
an internal control. The primer sequences were as fol-
lows: β-actin, 5′- AGAAGATCTGGCACCACACC 3′
(sense) and 5′-TACGACCAGAGGCATACAGG-3′ (anti-
sense); Pdx-1, 5′-CCCGAATGGAACCGAGCCT-3′ (sense)
and 5′-CCCGAGGTCACCGCACAAT-3′ (antisense); LXR-
β, 5′-AAGGACTTCACCTACAGCAAGGA-3′ (sense) and
5′–GAACTCGAAGATGGGATTGATGA-3′ (antisense).
Western blot
Pancreatic tissue homogenates were prepared in lysis
buffer (50 mM Tris–HCl, 2% SDS, and 10% glycerol)
supplemented with a protease inhibitor cocktail (Apply-
gen Inc. Beijing, China) as previously described [44].
Additionally, cellular lysates of NIT-1 cells were pre-
pared as previously depicted [45]. Proteins were resolved
by SDS-PAGE and immunoblotting assays were per-
formed as earlier mentioned [21]. The following anti-
bodies were used (1:1000 dilution unless otherwise
indicated): total eIF2α (sc-11386, 1:500), ATF4 (sc-200),
PDX-1 (sc-25403), and CHOP (sc-575), Bcl-2 (sc-7382)
(all from Santa Cruz Biotechnology), phospho-EIF2α
(Ser51, 9721) (Cell Signaling Technology, Danvers, MA)
and β-actin (Abmart, 1:2000). Protein bands were visual-
ized by chemiluminescence (ChemiScope2850, CLiNX
Science Instruments) and density was analyzed using the
Gel-Pro-Analyzer 3.1 software.
Biochemical analysis
Plasma triglycerides (TG), pancreas TG, plasma choles-
terol (CHO) and pancreas CHO were determined by
enzymatic colorimetric methods using commercial kits
(BioSino Inc., China). Plasma insulin was measured by
ELISA (Alpco. Inc., USA).
Cell viability and apoptosis assays
NIT-1 cells were seeded into 96-well plate at 2.3 × 104
cells/well, and cultured in DMEM/F12 medium supple-
mented with 10% FBS. When cells reached 80% conflu-
ence, they were incubated with 0.125 mM water-soluble
cholesterol (Sigma-Aldrich, St. Louis, MO) for 12 h in the
absence or presence of atorvastatin at concentration from10−9 to 10−5 M. Thereafter, NIT-1 cells were tested for via-
bility by using CCK-8 kit (Dojindo Laboratories, Kuma-
moto, Japan). The study was conducted for 3 times with 5
wells in each group. For apoptosis assays, NIT-1 cells were
seeded into 6-well plate at density of 4 × 105 cells/well.
When the cells were 80% confluent, they were incubated
with 0.125 mM water-soluble cholesterol for 18 h with or
without 10−8 M atorvastatin [46]. Then, the cells were
digested and fixed with 70% ethanol and incubated with
50 μg/mL propidium iodide and 1 μg/mL DNase-free
RNase. Stained cells were analyzed on a flow cytometer
(Beckman-coulter, Brea, CA), and the number of late-
stage apoptotic cells was analyzed by System II software.
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM). The data obtained in the present study
were analyzed using an ANOVA. A p value < 0.05 was
considered to be statistically significant.
Abbreviations
DIO: Diet-induced obesity; ER: Endoplasmic reticulum; UPR: Unfolded protein
response; PDX-1: Pancreatic and duodenal homeobox 1; LXR-β: Liver X
receptor β; eIF2α: Eukaryotic initiation factor 2α; ATF4: Activating
transcription factor 4; CHOP: CCAAT-enhancer-binding protein homologous
protein; IRE1α: Inositol-requiring 1α; PERK: Double-stranded RNA-dependent
protein kinase; ATF6: Activating transcription factor 6; CHO: Total cholesterol;
TG: Triglyceride; GIR: Glucose infusion rate; Bcl-2: B-cell lymphoma 2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZYC carried out studies including Real-time PCR, Western Blot and
immunofluorescence assays and all the data analysis. ZYC and SNL performed
the clamp test. CNL, SJS and QL participated in the animal in vivo experimental
test and biochemical analysis. LL participated in immunofluorescence assays
and data analysis. LHG participated in the sequence alignment. ZYC and ZFS
wrote the paper. ZFS designed the study and in coordination with all others
drafted the manuscript. CNL participated in revising the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was partly supported by the Key Project of the National Twelfth -Five
Year Research Program of China (No. 2012ZX09301002-004). We thank Mei Li
for technical help on manipulation of flow cytometry.
Received: 28 April 2014 Accepted: 17 June 2014
Published: 21 June 2014
References
1. Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB,
Chao YS, Bolognese JA: Cholesterol-lowering effect of mevinolin, an inhibitor
of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
J Clin Invest 1982, 69:913–919.
2. Mason RP, Walter MF, Day CA, Jacob RF: Intermolecular differences of
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to
distinctpharmacologic and pleiotropic actions. Am J Cardiol 2005, 96:11–23.
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection
Study of cholesterol lowering with simvastatin in 20,536 high-risk
individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.
4. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M: Dyslipidemia
and hyperglycemia predict coronary heart disease events in middle-aged
patients with NIDDM. Diabetes 1997, 46:1354–1359.
Chen et al. Lipids in Health and Disease 2014, 13:98 Page 9 of 10
http://www.lipidworld.com/content/13/1/985. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB,
Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood Institute;
American College of Cardiology Foundation; American Heart Association:
Implications of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.
6. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, Seshasai SR,
McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ,
Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM,
Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM,
Clearfield MB, Downs JR, Nakamura H, Ohashi Y: Statins and risk of incident risk
of developing type 2 diabetes: a collaborative meta-analysis of randomized
statin trials. Lancet 2010, 375:735–742.
7. Zhang N, Huan Y, Huang H, Song GM, Sun SJ, Shen ZF: Atorvastatin improves
insulin sensitivity in mice with obesity induced by monosodium glutamate.
Acta Pharmacol Sin 2010, 31:35–42.
8. Marchand KC, Arany EJ, Hill DJ: Effects of atorvastatin on the regeneration of
pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent.
Am J Physiol Endocrinol Metab 2010, 299:E92–E100.
9. Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L,
Roden M, Schloot NC, DIATOR Study Group: Improved preservation of residual
beta cell function by atorvastatin in patients with recent onset type 1
diabetes and high CRP levels (DIATOR trial). PLoS ONE 2012, 7:e33108.
10. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR,
Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and
the development of diabetes mellitus: evidence for a protectivetreatment
effect in the West of Scotland Coronary Prevention Study. Circulation 2001,
103:357–362.
11. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G,
Görgün C, Glimcher LH, Hotamisligil GS: Endoplasmic reticulum stress links
obesity, insulin action, and type 2 diabetes. Science 2004, 306:457–461.
12. Dodson G, Steiner D: The role of assembly in insulin’s biosynthesis.
Curr Opin Struct Biol 1998, 8:189–194.
13. Herbach N, Rathkolb B, Kemter E, Pichl L, Klaften M, De Angelis MH, Halban PA,
Wolf E, Aigner B, Wanke R: Dominant negative effects of a novel mutated
Ins2 allele causes early-onset diabetes and severe β-cell loss in Munich
Ins2C95S mutant mice. Diabetes 2007, 56:1268–1276.
14. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD,
Ron D: Diabetes mellitus and exocrine pancreatic dysfunction in perk−/−
mice reveals a role for translational control in secretory cell survival.
Mol Cell 2001, 7:1153–1163.
15. Zhang P, McGrath B, Li S, Frank A, Zambito F, Reinert J, Gannon M, Ma K,
McNaughton K, Cavener DR: The PERK eukaryotic initiation factor 2α
kinase is required for the development of the skeletal system, postnatal
growth, and the function and viability of the pancreas. Mol Cell Biol 2002,
22:3864–3874.
16. Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin AV,
Biden TJ: Endoplasmic reticulum stress contributes to beta cell apoptosis
in type 2 diabetes. Diabetologia 2007, 50:752–763.
17. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214–E223.
18. Wong V, Stavar L, Szeto L, Uffelman K, Wang CH, Fantus IG, Lewis GF:
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Atherosclerosis 2006, 184:348–355.
19. Furuya DT, Poletto AC, Favaro RR, Martins JO, Zorn TM, Machado UF: Anti-
inflammatory effect of atorvastatin ameliorates insulin resistance in
monosodium glutamate-treated obese mice. Metabolism 2010, 59:395–399.
20. Kim DS, Jeong SK, Kim HR, Kim DS, Chae SW, Chae HJ: Effects of triglyceride on
ER stress and insulin resistance. Biochem Biophys Res Commun 2007, 363:140–145.
21. Johnson JD, Ahmed NT, Luciani DS, Han Z, Tran H, Fujita J, Misler S, Edlund H,
Polonsky KS: Increased islet apoptosis in Pdx1+/− mice. J Clin Invest 2003,
111:1147–1160.
22. Lammert E, Cleaver O, Melton D: Induction of pancreatic differentiation by
signals from blood vessels. Science 2001, 294:564–567.
23. Duvillié B, Currie C, Chrones T, Bucchini D, Jami J, Joshi RL, Hill DJ: Increased
islet cell proliferation, decreased apoptosis, and greater vascularization
leading to beta-cell hyperplasia in mutant mice lacking insulin.
Endocrinology 2002, 143:1530–1537.
24. Guerci B, Böhme P, Kearney-Schwartz A, Zannad F, Drouin P: Endothelial
dysfunction and type 2 diabetes. Part 2: altered endothelial function and
the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001,
27:436–447.25. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide
synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266–24271.
26. Muniyappa R, Xu R, Ram JL, Sowers JR: Inhibition of Rho protein
stimulates iNOS expression in rat vascular smooth muscle cells. Am J
Physiol 2000, 278:H1762–H1768.
27. Tanabe K, Liu Y, Hasan SD, Martinez SC, Cras-Méneur C, Welling CM, Bernal-
Mizrachi E, Tanizawa Y, Rhodes CJ, Zmuda E, Hai T, Abumrad NA, Permutt
MA: Glucose and fatty acids synergize to promote B-cell apoptosis
through activation of glycogen synthase kinase 3β independent of JNK
activation. PLoS ONE 2011, 6:e18146.
28. Ryu D, Seo WY, Yoon YS, Kim YN, Kim SS, Kim HJ, Park TS, Choi CS, Koo SH:
Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin
resistance. Diabetes 2011, 60:1072–1081.
29. Zhang K, Kaufman RJ: From endoplasmic-reticulum stress to the inflammatory
response. Nature 2008, 454:455–462.
30. Yamaguchi H, Wang HG: CHOP is involved in endoplasmic reticulum stress-
induced apoptosis by enhancing DR5 expression in human carcinoma cells.
J Biol Chem 2004, 279:45495–45502.
31. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ: Chop deletion reduces
oxidative stress, improves beta cell function, and promotes cell survival in
multiple mouse models of diabetes. J Clin Invest 2008, 118:3378–3389.
32. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX,
Kuriakose G, Fisher EA, Marks AR, Ron D, Tabas I: The endoplasmic reticulum
is the site of cholesterol- induced cytotoxicity in macrophages. Nat Cell Biol
2003, 5:781–792.
33. Yoshida H, Haze K, Yanagi H, Yura T, Mori K: Identification of the cis-acting
endoplasmic reticulum stress response element responsible for transcriptional
induction of mammalian glucose-regulated proteins. Involvement of basic
leucine zipper transcription factors. J Biol Chem 1998, 273:33741–33749.
34. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human
studies revisited. FASEB J 2008, 22:659–661.
35. Center for Drug Evaluation and Research, Center for Biologics Evaluation and
Research: Estimating the safe starting dose in clinical trials for therapeutics in
adult healthy volunteers. Rockville, Maryland, USA: U.S. Food and Drug
Administration; 2002.
36. Haffner SM, American Diabetes Association: Dyslipidemia management in
adults with diabetes. Diabetes Care 2004, 27(1):S68–S71.
37. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T,
Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, REVERSAL
Investigators: Effect of intensive compared with moderate lipid-lowering
therapy on progression of coronary atherosclerosis: a randomized controlled
trial. JAMA 2004, 291:1071–1080.
38. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz
GG, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
(MIRACL) Study Investigators: High-dose atorvastatin reduces total plasma
levels of oxidized phospholipids and immune complexes present on
apolipoprotein B-100 in patients with acute coronary syndromes in the
MIRACL trial. Circulation 2004, 110:1406–1412.
39. Van Wissen S, Trip MD, Smilde TJ, De Graaf J, Stalenhoef AF, Kastelein JJ:
Differential hs-CRP reduction in patients with familial hypercholesterolemia
treated with aggressive or conventional statin therapy. Atherosclerosis 2002,
165:361–366.
40. Diabetes Atorvastin Lipid Intervention (DALI) Study Group: The effect of
aggressive versus standard lipid lowering by atorvastatin on diabetic
dyslipidemia: the DALI study: a double-blind, randomized, placebo-
controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Care 2001, 24:1335–1341.
41. Song GM, Huan Y, Sun SJ, Chen YT, Liu Q, Shen ZF: Biological activity of
EXf, a peptide analogue of exendin-4. Eur J Pharmacol 2010, 628:261–267.
42. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, Farb TB, Cao
JX, Cox AL, Michael MD, Gutierrez Sanfeliciano SM, Tebbe MJ, Coghlan MJ: Novel
small molecule glucagon-like peptide-1 receptor agonist stimulates insulin
secretion in rodents and from human islets. Diabetes 2010, 59:3099–3107.
43. Viegas MS, Martins TC, Seco F, Do Carmo A: An improved and cost-effective
methodology for the reduction of autofluorescence in direct
immunofluorescence studies on formalin-fixed paraffin-embedded
tissues. Eur J Histochem 2007, 51:59–66.
44. Goestemeyer A, Marks J, Srai SK, Debnam ES, Unwin RJ: GLUT2 protein at the
rat proximal tubule brush border membrane correlates with protein kinase
C (PKC)-betal and plasma glucose concentration. Diabetologia 2007,
50:2209–2217.
Chen et al. Lipids in Health and Disease 2014, 13:98 Page 10 of 10
http://www.lipidworld.com/content/13/1/9845. Fan H, Guo Y, Liang X, Yuan Y, Qi X, Wang M, Ma J, Zhou H: Hydrogen
sulfide protects against amyloid beta-peptide induced neuronal injury
via attenuating inflammatory responses in a rat model. J Biomed Res
2013, 27:296–304.
46. Kedi X, Ming Y, Yongping W, Yi Y, Xiaoxiang Z: Free cholesterol
overloading induced smooth muscle cells death and activated both ER-
and mitochondrial-dependent death pathway. Atherosclerosis 2009,
207:123–130.
doi:10.1186/1476-511X-13-98
Cite this article as: Chen et al.: Atorvastatin helps preserve pancreatic β
cell function in obese C57BL/6 J mice and the effect is related to
increased pancreas proliferation and amelioration of endoplasmic-
reticulum stress. Lipids in Health and Disease 2014 13:98.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
